Thanks for sharing your thoughts Dr.T. If you think the outcomes of phase 2b was going to be moot anyway then why did they run it - to be sure that they are not leaving money on the table? Anyway the cost and time to run it was cheap and the results known quickly so no time wasted there.
I agree the prophylactic use has a huge TAM and the question is how quickly we can get an approval.
If the therapeutic side is a no-go then why call this trial a success and also have a webinar after 4 days as many companies do it the same or next day? Is it because they still want to analyse what’s happening and what opportunities there may still be in reducing the symptoms in dengue and other flavi-viruses?
Just thinking out loud.
ILA Price at posting:
17.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)